NCT02429570View on ClinicalTrials.gov

Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary

NAActive, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 22, 2015

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Recurrent Brain MetastasesProgressive Brain Metastases
Interventions
DRUG

Meclofenamate

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11725

Memorial Sloan Kettering Cancer Center at Commack, Commack

18103

Lehigh Valley Health Network, Allentown

33143

Baptist Health South Florida, Miami

Unknown

Memorial Sloan Kettering Cancer Center, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02429570 - Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary | Biotech Hunter | Biotech Hunter